C3N-02252
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.430
- APICAL_SURFACE+0.330
- INTERFERON_GAMMA_RESPONSE+0.320
- KRAS_SIGNALING_DN+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.180
- APICAL_JUNCTION+0.150
- WNT_BETA_CATENIN_SIGNALING+0.150
- MYOGENESIS+0.140
- NOTCH_SIGNALING+0.110
- ALLOGRAFT_REJECTION+0.070
Top 10 suppressed
- PROTEIN_SECRETION-0.520
- ANDROGEN_RESPONSE-0.460
- TGF_BETA_SIGNALING-0.380
- TNFA_SIGNALING_VIA_NFKB-0.350
- CHOLESTEROL_HOMEOSTASIS-0.290
- ANGIOGENESIS-0.280
- MYC_TARGETS_V1-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.280
- UV_RESPONSE_DN-0.280
- APOPTOSIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0398 | Med | Medulloblastoma | 0.830 |
| 2 | MNG672 | — | — | 0.807 |
| 3 | C3L-02625 | — | cohortSQ2 | 0.782 |
| 4 | SRR975599 | — | — | 0.772 |
| 5 | SRR33532821 | — | D | 0.754 |
| 6 | MNG1106 | — | — | 0.752 |
| 7 | SRR12202481 | — | — | 0.750 |
| 8 | SRR33532764 | — | D | 0.741 |
| 9 | SRR4195656 | — | — | 0.737 |
| 10 | SRR10900002 | — | — | 0.735 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |